Experimental cell therapy targets Hard-to-Treat bile duct cancers

NCT ID NCT07614061

Recruiting now Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 03, 2026 · Last updated Jun 14, 2026 · Updated 3 times

Summary

This early-stage study tests a new treatment called BTC-Ag-T for people with advanced bile duct or gallbladder cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to check the safety of this approach and see if it can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact

Conditions

Explore the condition pages connected to this study.

BILIARY TRACT NEOPLASMS CHOLANGIOCARCINOMA, EXTRAHEPATIC CHOLANGIOCARCINOMA, INTRAHEPATIC CHOLANGIOCARCINOMA, PERIHILAR GALLBLADDER CANCER GALLBLADDER CANCER

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

ADVANCED BILIARY TRACT CANCER